Literature DB >> 27050856

Guillain-Barré syndrome associated with the Zika virus outbreak in Brazil.

Lucas Masiêro Araujo1, Maria Lucia Brito Ferreira2, Osvaldo Jm Nascimento1.   

Abstract

Zika virus (ZIKV) is now considered an emerging flavivirosis, with a first large outbreak registered in the Yap Islands in 2007. In 2013, a new outbreak was reported in the French Polynesia, with associated cases of neurological complications including Guillain-Barré syndrome (GBS). The incidence of GBS has increased in Brazil since 2015, what is speculated to be secondary to the ZIKV infection outbreak. The gold-standard test for detection of acute ZIKV infection is the polymerase-chain reaction technique, an essay largely unavailable in Brazil. The diagnosis of GBS is feasible even in resource-limited areas using the criteria proposed by the GBS Classification Group, which is based solely on clinical grounds. Further understanding on the relationship of ZIKV with neurological complications is a research urgency.

Entities:  

Mesh:

Year:  2016        PMID: 27050856     DOI: 10.1590/0004-282X20160035

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  55 in total

1.  High-Throughput Zika Viral Titer Assay for Rapid Screening of Antiviral Drugs.

Authors:  Emily M Lee; Steven A Titus; Miao Xu; Hengli Tang; Wei Zheng
Journal:  Assay Drug Dev Technol       Date:  2019-04       Impact factor: 1.738

Review 2.  Guillain-Barré syndrome: a century of progress.

Authors:  John A Goodfellow; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2016-11-18       Impact factor: 42.937

3.  Efficiencies and kinetics of infection in different cell types/lines by African and Asian strains of Zika virus.

Authors:  Suzane Ramos da Silva; Fan Cheng; I-Chueh Huang; Jae U Jung; Shou-Jiang Gao
Journal:  J Med Virol       Date:  2018-10-09       Impact factor: 2.327

Review 4.  Host-Virus Interaction of ZIKA Virus in Modulating Disease Pathogenesis.

Authors:  Nanda Kishore Routhu; Siddappa N Byrareddy
Journal:  J Neuroimmune Pharmacol       Date:  2017-03-27       Impact factor: 4.147

Review 5.  Zika clinical updates: implications for pediatrics.

Authors:  Kristina Adachi; Karin Nielsen-Saines
Journal:  Curr Opin Pediatr       Date:  2018-02       Impact factor: 2.856

6.  The FDA-approved drug sofosbuvir inhibits Zika virus infection.

Authors:  Kristen M Bullard-Feibelman; Jennifer Govero; Zhe Zhu; Vanessa Salazar; Milena Veselinovic; Michael S Diamond; Brian J Geiss
Journal:  Antiviral Res       Date:  2016-11-27       Impact factor: 5.970

Review 7.  Current concerns and perspectives on Zika virus co-infection with arboviruses and HIV.

Authors:  Hussin A Rothan; Mehdi R M Bidokhti; Siddappa N Byrareddy
Journal:  J Autoimmun       Date:  2018-01-17       Impact factor: 7.094

8.  Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model.

Authors:  Justin G Julander; Venkatraman Siddharthan; Joe Evans; Ray Taylor; Kelsey Tolbert; Chad Apuli; Jason Stewart; Preston Collins; Makda Gebre; Skot Neilson; Arnaud Van Wettere; Young-Min Lee; William P Sheridan; John D Morrey; Y S Babu
Journal:  Antiviral Res       Date:  2016-11-10       Impact factor: 5.970

9.  Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen.

Authors:  Miao Xu; Emily M Lee; Zhexing Wen; Yichen Cheng; Wei-Kai Huang; Xuyu Qian; Julia Tcw; Jennifer Kouznetsova; Sarah C Ogden; Christy Hammack; Fadi Jacob; Ha Nam Nguyen; Misha Itkin; Catherine Hanna; Paul Shinn; Chase Allen; Samuel G Michael; Anton Simeonov; Wenwei Huang; Kimberly M Christian; Alison Goate; Kristen J Brennand; Ruili Huang; Menghang Xia; Guo-Li Ming; Wei Zheng; Hongjun Song; Hengli Tang
Journal:  Nat Med       Date:  2016-08-29       Impact factor: 53.440

Review 10.  Zika virus: An update on epidemiology, pathology, molecular biology, and animal model.

Authors:  Suzane Ramos da Silva; Shou-Jiang Gao
Journal:  J Med Virol       Date:  2016-05-05       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.